Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › CCR2+ hematopoietic stem cells mediate T cell activation in adoptive cell therapy

CCR2+ hematopoietic stem cells mediate T cell activation in adoptive cell therapy

US Patent 11464805 · Granted Oct 11, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Methods, kits, and compositions for enhancing cellular therapy2025
Compositions, methods and kits for eliciting an immune response2024
Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibit2024
Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibit2024
Tetanus toxoid and CCL3 improve DC vaccines2023
Methods, kits, and compositions for enhancing cellular therapy2023
Compositions, methods and kits for eliciting an immune response2022
Compositions, methods and kits for eliciting an immune response2022
Compositions, methods and kits for eliciting an immune response2022
Compositions, methods and kits for eliciting an immune response2022
Tetanus toxoid and CCL3 improve DC vaccines2021
Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibit2020